CDD-0078

From Food & Medicine Encyclopedia

CDD-0078
[[File:|frameless|220px|alt=|Chemical structure of CDD-0078]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG


CDD-0078 is an investigational drug currently under development for the treatment of neurodegenerative diseases. It is a small molecule that has shown promise in preclinical studies for its potential to modulate specific pathways involved in neuronal survival and function.

Mechanism of Action[edit]

CDD-0078 is believed to exert its effects by targeting the protein kinase pathways that are crucial for cell survival and apoptosis. Specifically, it modulates the activity of kinase enzymes that are involved in the regulation of neurotrophic factors, which are essential for the growth, maintenance, and survival of neurons.

Pharmacokinetics[edit]

The pharmacokinetic profile of CDD-0078 is characterized by its high bioavailability and moderate half-life, allowing for once-daily dosing. It is primarily metabolized in the liver and excreted via the renal pathway. Studies have shown that CDD-0078 has a favorable safety profile with minimal adverse effects.

Clinical Trials[edit]

As of the latest updates, CDD-0078 is in Phase II clinical trials. These trials are focused on evaluating its efficacy and safety in patients with early-stage Alzheimer's disease. Preliminary results have indicated a potential improvement in cognitive function and a reduction in the progression of neurodegenerative symptoms.

Potential Applications[edit]

Beyond Alzheimer's disease, CDD-0078 is being explored for its potential use in other neurodegenerative conditions such as Parkinson's disease and Huntington's disease. Its ability to modulate neurotrophic pathways makes it a candidate for a broad range of neurological disorders.

Research and Development[edit]

The development of CDD-0078 is being spearheaded by a collaboration between academic institutions and pharmaceutical companies. Ongoing research is focused on optimizing its therapeutic effects and understanding its long-term impact on neuronal health.

Also see[edit]


This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Neuroscience
Basic
science
Clinical
neuroscience
Cognitive
neuroscience
Interdisciplinary
fields
Concepts
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends ✔ Tele visits available with certain limitations Learn more:

Advertise on WikiMD

WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=CDD-0078&oldid=6024026"